Pooled clinical trial analysis of tiotropium safety

Chest

Volumn 130, Issue 6, 2006, Pages 1695-1703

  Kesten, Steven ^a,d   Jara, Michele ^b,d   Wentworth, Charles ^c,d   Lanes, Stephan ^a,d  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Epidemiology Consulting LLC   (United States)

^c Analytic Consulting Solutions   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

COPD; Drug safety; Tiotropium

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE;

ABDOMINAL PAIN; ACCURACY; AGITATION; ANALYTIC METHOD; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANXIETY DISORDER; ARTICLE; ASTHMA; BRADYCARDIA; BRONCHITIS; BRONCHOSPASM; CALCULATION; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DATA BASE; DEHYDRATION; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DIZZINESS; DRUG APPROVAL; DRUG SAFETY; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGITIS; EVALUATION; EXTRASYSTOLE; GLAUCOMA; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSOMNIA; IRREGULAR HEART BEAT; KIDNEY FAILURE; LARYNGITIS; LOWER RESPIRATORY TRACT INFECTION; MANTEL HAENSZEL TEST; MENTAL DISEASE; META ANALYSIS; MICTURITION DISORDER; MUSCULOSKELETAL DISEASE; MYCOSIS; NAUSEA; NOSE CONGESTION; PHARYNGITIS; POOLED ANALYSIS; PRIORITY JOURNAL; PROSTATE DISEASE; PRURITUS; PURULENT SPUTUM; RASH; RESPIRATORY FAILURE; RIGHT VENTRICULAR HEART FAILURE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINUSITIS; STRESS; SYNCOPE; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE RETENTION; URTICARIA; WHEEZING; XEROSTOMIA;

EID: 33845938174     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.6.1695     Document Type: Article

References (29)

1. Disse B, Speck GA, Rotninger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64:457-4 64
2. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224
3. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209-216
4. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399-404
5. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55
6. O'Donnell D, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832-840
7. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178
8. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med 2005; 143:319-326
9. Spiriva HandiHaler tiotropium bromide inhalation powder [US package insert]. Ingelheim, Germany: Boehringer Ingelheim International GmbH, 2004
10. Atrovent (ipratropium bromide) inhalation aerosol [US package insert]. Ingelheim, Germany: Boehringer Ingelheim International GmbH, 2002
11. Morganroth J, Golisch W, Kesten S. Electrocardiographic monitoring in COPD patients receiving tiotropium. COPD 2004; 1:181-190
12. Rothman KJ, Greenland S. Measures of disease frequency. In: Rothman KJ, Greenland S. Modern epidemiology, 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers, 1998; 29-46
13. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2:121-145
14. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127:809-817
15. Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004; 125:1726-1734
16. Calverley PMA, Lee A, Towse L, et al. The effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58:855-860
17. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1136-1142
18. Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease. Eur Respir J 1995; 8:1506-1513
19. Celli B, ZuWallack R, Wang S, et al. Improvements in resting inspiratory capacity and hyperinflation with tiotropium in COPD with increased static lung volumes. Chest 2003; 124:1743-1748
20. McNicholas WT, Calverly PMA, Lee A, et al. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23:825-831
21. Brown JE, Taylor P. Muscarinic receptor agonists and antagonists. In: Gilman AG, Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed. New York, NY: McGraw-Hill Book, 2001; 162-168
22. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, MD: National Heart, Lung, and Blood Institute, April 2001. Available at: www.goldcopd.com. Accessed November 5, 2004
23. Celli BR, MacNee W, and ATS/ERS Task Force Committee Members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946
24. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333-339
25. 1, the Lung Health Study. JAMA 1994; 272:1497-1505
26. Lanes S, Golisch W, Mild J. Ipratropium and Lung Health Study. Am J Respir Crit Care Med 2003; 167:801
27. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of B-agonists in patients with asthma and COPD. Chest 2004; 125:2309-2321
28. Psaty BM, Furberg CD. Cox-2 inhibitors: lessons in drug safety. N Engl J Med 2005; 352:1133-1135
29. Center for Drug Evaluation and Research, United States Food and Drug Administration. FDA public health advisory, worsening depression and suicidality in patients being treated with antidepressant medications. Available at: www.fda.gov/ cder/drug/antidepressants/AntidepressanstPHA.htm. Accessed December 11, 2004